Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa

Table 1

Patient characteristics and mutations at failure of second-line therapy.

Variable		Median (inter quartile range)
	Median (inter quartile range)	No PI major mutations (𝑛=70)	PI major mutations (𝑛=5)
Age (years)	34 (29–40)
CD4+ T-cells/mm^3	141 (75–245)	138 (80–229)	246 (194–254)
HIV-1 RNA (copies/mL)	184,779 (8790–166,300)	61000 (15000–155000)	3260 (2200–33000)
Time on second-line (months)	16 (7–18)
Regimens	𝑛
LPV/r, AZT, ddI	53
LPV/r, 3TC, AZT	8
LPV/r, 3TC, TNF	4
LPV/r, 3TC, ABC	2
LPV/r, AZT, d4T	2
LPV/r, ddI, TNF	2
LPV/r, 3TC, ddI	1
LPV/r, 3TC, EFV	1
LPV/r, AZT, EFV	1
LPV/r, FTC, TNF	1
Resistance Mutations	𝑛(%)
NRTI mutations	26 (35%)
M184V	15 (20%)
K65R	0 (0%)
Q151M	1 (1%)
TAMs	10 (13%)
NNRTI mutations	39 (52%)
K103N	16 (21%)
V106M	9 (12%)
Any PR mutations (major and minor)	67 (89%)
Major LPV mutations	5 (7%)
M46I, L76V	1
M46I	1
L33F, I54S, V82A, I84V	1
L33F, M46I, I54V, I84V, L90M	1
M46I, I54V, L76V	1